Get the Stockscreener App
53.62
5.47%
-3.10
After Hours:
53.60
-0.02
-0.04%
Soleno Therapeutics Inc stock is traded at $53.62, with a volume of 3.12M.
It is down -5.47% in the last 24 hours and down -35.68% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$56.72
Open:
$56.04
24h Volume:
3.12M
Relative Volume:
2.06
Market Cap:
$2.85B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-17.89
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-23.15%
1M Performance:
-35.68%
6M Performance:
+14.82%
1Y Performance:
+8.08%
1-Day Range:
$52.37
$56.17
1-Week Range:
$50.63
$72.99
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
53.62 | 3.19B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
How to track smart money flows in Soleno Therapeutics Inc.Earnings Recap Summary & Weekly High Return Stock Opportunities - Newser
News impact scoring models applied to Soleno Therapeutics Inc.Market Weekly Review & Safe Capital Growth Tips - Newser
Using flow based indicators on Soleno Therapeutics Inc.2025 Volatility Report & Verified Entry Point Detection - Newser
Multi factor analysis applied to Soleno Therapeutics Inc.Weekly Stock Recap & High Accuracy Trade Alerts - Newser
Understanding Soleno Therapeutics Inc.’s price movementJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - Newser
Is Soleno Therapeutics Inc. showing signs of accumulationJuly 2025 Review & Entry Point Confirmation Signals - Newser
Using fundamentals and technicals on Soleno Therapeutics Inc.Bond Market & Fast Entry Momentum Trade Alerts - Newser
Soleno Therapeutics (NASDAQ:SLNO) Trading Down 8.9%What's Next? - MarketBeat
Visual trend scoring systems applied to Soleno Therapeutics Inc.2025 Price Momentum & Low Drawdown Investment Ideas - Newser
Soleno Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Woodline Partners LP Grows Stock Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Smart tools for monitoring Soleno Therapeutics Inc.’s price action2025 Historical Comparison & Accurate Intraday Trade Tips - Newser
Optimize Financial Inc Makes New Investment in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Trexquant Investment LP Makes New $1.21 Million Investment in Soleno Therapeutics, Inc. $SLNO - MarketBeat
What to do if you’re stuck in Soleno Therapeutics Inc.Trade Performance Summary & Community Verified Watchlist Alerts - Newser
Fred Alger Management LLC Has $2.89 Million Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Inc. stock trend outlook and recovery pathTrade Exit Summary & Risk Controlled Stock Alerts - Newser
Samlyn Capital LLC Lowers Stock Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Using Ichimoku Cloud for Soleno Therapeutics Inc. technicalsJuly 2025 Closing Moves & Momentum Based Trading Signals - Newser
Will Soleno Therapeutics Inc. continue its uptrend2025 Market Outlook & AI Forecasted Entry/Exit Points - Newser
Key resistance and support levels for Soleno Therapeutics Inc.2025 Top Gainers & Technical Pattern Alert System - Newser
Technical signs of recovery in Soleno Therapeutics Inc.July 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - Newser
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Granahan Investment Management LLC Invests $2.32 Million in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire Inc.
Soleno Therapeutics stock maintains Buy rating at TD Cowen as Vykat XR launch exceeds expectations - Investing.com Canada
Stifel reiterates Buy rating on Soleno Therapeutics stock amid safety concerns - Investing.com Australia
Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Are Legal Probes Shaping Trust in Soleno Therapeutics’ (SLNO) Drug Pipeline and Investor Relations? - Yahoo Finance
10 Stocks Melt Down in Hours - Insider Monkey
Soleno Therapeutics (SLNO) Falls Hard on Patient Death - Insider Monkey
Market reaction to Soleno Therapeutics Inc.’s recent newsJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - Newser
Is it time to cut losses on Soleno Therapeutics Inc.2025 Major Catalysts & Smart Allocation Stock Tips - Newser
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura - The Globe and Mail
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside - Stocktwits
Soleno Therapeutics stock drops on FAERS update, Baird maintains Outperform rating - Investing.com
Soleno Therapeutics stock maintains Buy rating at TD Cowen despite safety events - Investing.com
Soleno Therapeutics Addresses FDA Adverse Event Report - TipRanks
Soleno Therapeutics says death of patient not related to Vykat XR treatment - MarketScreener
Soleno drops as patient on Vykat XR dies (SLNO:NASDAQ) - Seeking Alpha
SLNO Investor News: If You Have Suffered Losses in Soleno - GlobeNewswire
Soleno Therapeutics stock falls after patient death report By Investing.com - Investing.com Canada
Soleno reports death of patient who took genetic disorder treatment - MarketScreener
A Look at Soleno Therapeutics’s Valuation Following Legal Probes Into VYKAT XR Safety and Business Practices - Yahoo Finance
Scientech Research LLC Boosts Stake in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Inc. stock trendline breakdownJuly 2025 Review & Weekly Breakout Watchlists - Newser
Regression analysis insights on Soleno Therapeutics Inc. performanceTreasury Yields & AI Powered Trade Plan Recommendations - Newser
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):